Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status

Due to the high variance in response rates concerning anti-PD1 immunotherapy (IT), there is an unmet need to discover innovative biomarkers to predict immune checkpoint inhibitor (ICI)-efficacy. Our study included 62 Caucasian advanced-stage non-small cell lung cancer (NSCLC) patients treated with a...

詳細記述

書誌詳細

出版年:	OncoImmunology
主要な著者:	David Dora, Balazs Ligeti, Tamas Kovacs, Peter Revisnyei, Gabriella Galffy, Edit Dulka, Dániel Krizsán, Regina Kalcsevszki, Zsolt Megyesfalvi, Balazs Dome, Glen J. Weiss, Zoltan Lohinai
フォーマット:	論文
言語:	英語
出版事項:	Taylor & Francis Group 2023-12-01
主題:	Anti-PD1 immunotherapy gut microbiome metagenome pathways NSCLC PD-L1
オンライン･アクセス:	https://www.tandfonline.com/doi/10.1080/2162402X.2023.2204746